Literature DB >> 14984023

Role of natural interferon-alpha producing cells (plasmacytoid dendritic cells) in autoimmunity.

Lars Rönnblom1, Maija-Leena Eloranta, Gunnar V Alm.   

Abstract

The type I interferons (IFNs) have antiviral, cytostatic and prominent immunomodulatory effects, which all are of great importance during viral infections. However, prolonged exposure of the immune system to type I IFN can break tolerance and initiate an autoimmune reaction, eventually leading to autoimmune disease. Recent observations in patients with systemic lupus erythematosus (SLE) have revealed that such individuals have endogenous IFN-alpha inducers, causing an ongoing IFN-alpha production and consequently a continuous stimulation of the immune system. These IFN-alpha inducers consist of small immune complexes (IC) containing DNA or RNA and act on the principal IFN-alpha producing cell, the natural IFN-alpha producing cell (NIPC), also termed the plasmacytoid dendritic cell (PDC). The NIPC/PDC is a key cell in both the innate and adaptive immune response but can also, either directly or via produced IFN-alpha, have a pivotal role in autoimmunity. In this review we summarize recent data concerning NIPC/PDC, including their activation, regulation, function and possible role in autoimmune diseases, especially SLE.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14984023     DOI: 10.1080/08916930310001602128

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  35 in total

1.  Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells.

Authors:  Timothy E Quan; Robert M Roman; Benjamin J Rudenga; V Michael Holers; Joseph E Craft
Journal:  Arthritis Rheum       Date:  2010-06

Review 2.  Dendritic cells: potential triggers of autoimmunity and targets for therapy.

Authors:  J A Hardin
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

3.  The interferon signature and STAT1 expression in rheumatoid arthritis synovial fluid macrophages are induced by tumor necrosis factor α and counter-regulated by the synovial fluid microenvironment.

Authors:  Rachael A Gordon; Galina Grigoriev; Angela Lee; George D Kalliolias; Lionel B Ivashkiv
Journal:  Arthritis Rheum       Date:  2012-10

Review 4.  dsRNA sensors and plasmacytoid dendritic cells in host defense and autoimmunity.

Authors:  Yaming Wang; Melissa Swiecki; Stephen A McCartney; Marco Colonna
Journal:  Immunol Rev       Date:  2011-09       Impact factor: 12.988

Review 5.  Role of type I interferons in the activation of autoreactive B cells.

Authors:  Kerstin Kiefer; Michael A Oropallo; Michael P Cancro; Ann Marshak-Rothstein
Journal:  Immunol Cell Biol       Date:  2012-03-20       Impact factor: 5.126

Review 6.  Viruses and salivary gland disease (SGD): lessons from HIV SGD.

Authors:  L Jeffers; J Y Webster-Cyriaque
Journal:  Adv Dent Res       Date:  2011-04

Review 7.  Self-dsDNA in the pathogenesis of systemic lupus erythematosus.

Authors:  Y Bai; Y Tong; Y Liu; H Hu
Journal:  Clin Exp Immunol       Date:  2017-09-15       Impact factor: 4.330

8.  In vivo ablation of plasmacytoid dendritic cells inhibits autoimmunity through expansion of myeloid-derived suppressor cells.

Authors:  Marianna Ioannou; Themis Alissafi; Louis Boon; Dimitrios Boumpas; Panayotis Verginis
Journal:  J Immunol       Date:  2013-02-04       Impact factor: 5.422

9.  Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion.

Authors:  Bernd Jahrsdörfer; Angelika Vollmer; Sue E Blackwell; Julia Maier; Kai Sontheimer; Thamara Beyer; Birgit Mandel; Oleg Lunov; Kyrylo Tron; G Ulrich Nienhaus; Thomas Simmet; Klaus-Michael Debatin; George J Weiner; Dorit Fabricius
Journal:  Blood       Date:  2009-12-03       Impact factor: 22.113

10.  Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8.

Authors:  Dipyaman Ganguly; Georgios Chamilos; Roberto Lande; Josh Gregorio; Stephan Meller; Valeria Facchinetti; Bernhard Homey; Franck J Barrat; Tomasz Zal; Michel Gilliet
Journal:  J Exp Med       Date:  2009-08-24       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.